The FDA has granted expanded access to Revolution Medicines' RAS(ON) inhibitor daraxonrasib for metastatic pancreatic cancer, prior to formal approval...
Revolution Medicines (RVMD) saw its stock rise 7.2% after reporting a statistically significant improvement in progression-free and overall survival f...
Neutral
B. Metzler seel. Sohn & Co. AG lessened its stake in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 32.5% in the 4th quarter, according to ...
Neutral
Revolution Medicines (NasdaqGS:RVMD) announced preclinical data for RM-055, a new class of catalytic RAS(ON) inhibitors, and updated first-line clinic...
Neutral
Revolution Medicines Inc. (RVMD) presented updated Phase 1 clinical trial results for zoldonrasib at the AACR conference, showing promising data for t...
Neutral
Revolution Medicines, Inc. has issued $500 million of 0.50% Convertible Senior Notes due 2033. These senior unsecured notes carry a low interest rate,...